SEC Tracker
Get the app

Madrigal Pharmaceuticals MDGL

Madrigal Pharmaceuticals reports strong Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Third-quarter 2026 Rezdiffra net sales of $431.3 million, up 50% year-over-year
  2. Rezdiffra reaches blockbuster status with $1.1 billion in year-to-date net sales
  3. Cash and cash equivalents of $961.8 million as of Sept. 30, 2026
  4. MAESTRO-CSPH Phase 3 trial expected to start in 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Madrigal Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release with details about the company's performance.
  2. The press release is incorporated by reference into the Form 8-K.
  3. The press release states that Rezdiffra net sales for the third quarter of 2026 were $431.3 million, a 50% increase from the previous year.
  4. The drug achieved profitability for the first time in the quarter.
  5. Year-to-date net sales of Rezdiffra reached $1.1 billion, meeting blockbuster status.
  6. The U.S. F2-F3 MASH market grew to over 530,000 addressable patients by June 30, 2026, with expected growth of more than 30% by the end of 2026.
  7. Madrigal reported cash, cash equivalents, restricted cash, and marketable securities of $961.8 million as of September 30, 2026.
  8. Reed, M.D., Ph.D., to its Board of Directors.

8 of 8 claims matched the filing text.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2026, Madrigal Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2026.1 A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2

The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

99.1 Press Release Dated November 3, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MADRIGAL PHARMACEUTICALS, INC.

By: /s/ Mardi Dier

Name: Mardi Dier

Title: Executive Vice President and Chief Financial Officer

Date: November 3, 2026

3

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

• Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%3; achieved first quarter of profitability4

• Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion5

• As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand • U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addressable patients through June 30, 2026, on track for more than 30% growth by YE266

• Madrigal strengthens its leadership position in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH outcomes clinical trial; MAESTRO-NASH OUTCOMES on track, data expected late 2027

• Reports cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of Sept.7 730, 20267

• Appointed John C. Reed, M.D., Ph.D., to Board of Directors8

• Company to host conference call today, Nov. 3, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Nov. 3, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.